Physician profile
Maureen Roye
NPI 1518740513
$205.50
in general payments reported to CMS, 2019-2025
4 companies · $49.40 in 2025
The $49.40 reported for 2025 was less than what a typical Advanced Practice Midwife provider received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $115 · 2024: $41.52 · 2025: $49.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $133.83 | 2023-2024 | Veozah |
| Sage Therapeutics, LLC | $29.00 | 2025 | Zurzuvae |
| Organon LLC | $22.27 | 2024 | |
| Coopersurgical, INC. | $20.40 | 2025 | Paragard T 380a |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Roye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.